Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

59 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-29

Study Completion Date

2019-10-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objectives of this study:

* To investigate the safety and tolerability of ascending repeated oral doses of BAY1902607 in healthy subjects (Part 1).
* To investigate the effect of BAY1902607 on the pharmacokinetics (PK) of a sub-therapeutic 1 mg dose of midazolam (Part 1).
* To investigate the safety, tolerability and efficacy of BAY1902607 in patients with refractory chronic cough (Part 2).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients

NCT03310645

Cough

COMPLETED PHASE1/PHASE2

This Study in Healthy Men Tests How Different Doses of BI 1265162 Are Taken up in the Body and How Well They Are Tolerated.

NCT03576144

Healthy

COMPLETED PHASE1

A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough

NCT03372603

Cough

TERMINATED PHASE1/PHASE2

Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

NCT06175351

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)

NCT01703052

Chronic Obstructive Pulmonary Disease (COPD)

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cough

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Part 1: Sequential parallel-group Part 2: Two-arm crossover

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose 1 of BAY1902607

Part 1: From Day 1 until Day 12 the dose 1 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 1 of BAY1902607 will be given only once.

Group Type EXPERIMENTAL

BAY1902607

Intervention Type DRUG

3 different doses over the course of part 1 and 4 different doses over the course of part 2.

Midazolam

Intervention Type DRUG

Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.

Dose 2 of BAY1902607

Part 1: From Day 1 until Day 12 the dose 2 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 2 of BAY1902607 will be given only once.

Group Type EXPERIMENTAL

BAY1902607

Intervention Type DRUG

3 different doses over the course of part 1 and 4 different doses over the course of part 2.

Midazolam

Intervention Type DRUG

Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.

Dose 3 of BAY1902607

Part 1: From Day 1 until Day 12 the dose 3 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 3 of BAY1902607 will be given only once.

Group Type EXPERIMENTAL

BAY1902607

Intervention Type DRUG

3 different doses over the course of part 1 and 4 different doses over the course of part 2.

Midazolam

Intervention Type DRUG

Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.

Matching placebo

Part 1: From Day 1 until Day 12 the matching placebo will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, matching placebo will be given only once.

Group Type EXPERIMENTAL

Matching placebo

Intervention Type DRUG

Matching placebo for BAY1902607

Midazolam

Intervention Type DRUG

Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.

BAY1902607+Matching Placebo

Part 2:

Randomized crossover design in cough patients 4 different doses of BAY1902607+matching placebo

Group Type EXPERIMENTAL

BAY1902607

Intervention Type DRUG

3 different doses over the course of part 1 and 4 different doses over the course of part 2.

Matching placebo

Intervention Type DRUG

Matching placebo for BAY1902607

Matching Placebo+BAY1902607

Part 2:

Randomized crossover design in cough patients Matching placebo+4 different doses of BAY1902607

Group Type EXPERIMENTAL

BAY1902607

Intervention Type DRUG

3 different doses over the course of part 1 and 4 different doses over the course of part 2.

Matching placebo

Intervention Type DRUG

Matching placebo for BAY1902607

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BAY1902607

3 different doses over the course of part 1 and 4 different doses over the course of part 2.

Intervention Type DRUG

Matching placebo

Matching placebo for BAY1902607

Intervention Type DRUG

Midazolam

Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Part 1:

* Male; healthy according to complete medical history, including the physical examination, vital signs (blood pressure, heart rate), 12-lead ECG, clinical laboratory tests
* Age: 18-45 years (inclusive) at the first screening visit
* Non-smoker for at least 6 months and with a pack year history of equal to or less than 5 years
* Subjects, who are sexually active and have not been surgically sterilized, must agree to use two reliable and acceptable methods of contraception simultaneously, when having sexual intercourse with women of childbearing potential (one method used by the subject, one method used by the partner) during the study and for 90 days after receiving the investigational medicinal product, and not to act as sperm donor for 90 days after dosing. \[Acceptable methods of contraception include for example: (a) condoms (male or female) with or without a spermicidal agent, (b) diaphragm or cervical cap with spermicide, (c) intrauterine device, (d) hormone-based contraception\]

Part 2:

* Age: ≥18 years at the first screening visit
* Refractory chronic cough for at least one year that has been shown to be unresponsive to treatment of cough according to the 2006 British Thoracic Society (BTS) guideline
* Score of ≥ 40 mm on the Cough Severity visual analogue scale (VAS) at screening
* For female patients:

Confirmed post-menopausal woman (defined as exhibiting spontaneous amenorrhea for at least 12 months before screening or as exhibiting spontaneous amenorrhea for 6 months before screening with documented serum follicle-stimulating hormone (FSH) levels \> 40 mIU/mL) or Woman without childbearing potential based on surgical treatment at least 6 weeks before screening, such as bilateral tubal ligation, bilateral oophorectomy with or without hysterectomy (documented by medical report verification) or Woman of childbearing potential that agrees to use two reliable and acceptable methods of contraception simultaneously (one method used by the study patient and one method used by the partner) during the study and for at least 31 days (1 average menstrual cycle of 28 days plus approx. 5 half-lives of BAY 1902607) after the last dose. In addition during the study and for at least 31 days after the last dose women of child bearing potential are not allowed to donate oocytes.

Exclusion Criteria

Part 1:

* Relevant diseases potentially interfering with the study objectives (e.g. respiratory diseases) within the four weeks before screening or between screening and randomization
* Any febrile illness within the four weeks before screening or between screening and randomization
* Medical history of hypogeusia/dysgeusia or the subject has a dysfunction in his ability to taste, as revealed by the taste-disturbance questionnaire during screening and the predose procedures

Part 2:

* FEV1(Forced Expiratory Volume in 1 second) or FVC(Forced Vital Capacity ) of less than 60% of predicted normal, at screening
* History of upper or lower respiratory tract infection or recent significant change in pulmonary status within the 4 weeks before screening
* Current smoking habit or history of smoking within the 6 months before the screening visit
* History of smoking (at any time) for more than 20 pack-years in total (20 cigarettes per pack)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No